Last reviewed · How we verify
Tongxinluo
At a glance
| Generic name | Tongxinluo |
|---|---|
| Also known as | Tongxinluo capsule, Yiling Pharmaceutical，Z19980015 |
| Sponsor | Qilu Hospital of Shandong University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Clinical Study of Tongxinluo Capsule in Preventing and Treating Restenosis After Intracranial and External Arterial Stenting (PHASE4)
- Tongxinluo Capsule in the Treatment of Cerebral Small Vessel Disease-A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Study（TOPS-CSVD） (PHASE4)
- Cohort Study on Treatment of Cardiovascular Diseases With Traditional Chinese Medicine
- Tongxinluo Capsule for Coronary Microvascular Disease (PHASE4)
- China Tongxinluo Study for Myocardial Protection in Patients With Acute Myocardial Infarction (PHASE4)
- Retrospective Clinical Study on Adjuvant Treatment of Coronary Heart Disease Angina Pectoris With Chinese Patent Medicine
- Clinical Study on Adjuvant Treatment of Coronary Heart Disease Angina Pectoris With Chinese Patent Medicine
- Tongxinluo Capsule in Ischemic Stroke Patients（TISS) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tongxinluo CI brief — competitive landscape report
- Tongxinluo updates RSS · CI watch RSS
- Qilu Hospital of Shandong University portfolio CI